Arbutus Biopharma Corp (NAS:ABUS)
$ 3.34 -0.29 (-7.99%) Market Cap: 630.32 Mil Enterprise Value: 557.49 Mil PE Ratio: 0 PB Ratio: 5.22 GF Score: 60/100

Q3 2022 Arbutus Biopharma Corp Earnings Call Transcript

Nov 09, 2022 / 01:45PM GMT
Release Date Price: $2.44 (-0.81%)
Operator

Good day and thank you for standing by, and welcome to Arbutus Biopharma Corporation's 2022 Third Quarter Financial Results and Corporate Update Conference Call. (Operator Instructions) Please be advised that today's conference is being recorded.

I would now like to hand the conference over to your speaker today, Lisa Caperelli, Vice President of Investor Relations. You may begin.

Lisa M. Caperelli
Arbutus Biopharma Corporation - VP of IR

Thanks, Justin. Good morning, everyone, and thank you for joining Arbutus' third quarter 2022 financial results and corporate update call.

Joining me today from the Arbutus executive team are Bill Collier, President and Chief Executive Officer; David Hastings, Chief Financial Officer; Dr. Gaston Picchio, Chief Development Officer; and Dr. Mike Sofia, Chief Scientific Officer. Bill will begin with a corporate update, followed by Dave, who will provide a review of the company's third quarter 2022 financial results. After opening remarks, we will open the call for Q&A. Gaston and Mike will be available to

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot